ZEB2 and ovarian cancer: Several of them inhibit Zeb2 expression leading to decreased EMT, such as miR-132 in colorectal cancer [215] and lung cancer [216], miR-153 in ovarian cancer [217], miR-154 in NLCLC [218], miR-203 in adenocarcinoma [219] and nasopharyngeal carcinoma [220], miR-338 in gastric cancer [221], and members of the miR-200 family in glioma cells [222], gastric carcinoma [223,224], and NSCLC [225], while no evidence has been reported to date on up-regulation of Zeb2 by microRNA deregulation.